The Move to Repurpose Drugs to Treat the Novel Coronavirus: Status

The Move to Repurpose Drugs to Treat the Novel Coronavirus: Status

NBC News recently reported that along with the big push for new COVID-19 vaccines, there are a number of initiatives around the globe to repurpose existing drugs to potentially treat the coronavirus. Although the quest for a novel cure or vaccine will intensify, this will take time and effort. In the meantime, as a pandemic intensifies, the need for action is now. Hence older drugs are being explored by drug companies and researchers around the globe.

Thanks to the concise and crisp reporting of Ms. Emily Siegel,—assistant producer, NBC News Investigative Unit—TrialSite News summarizes the report and encourages readers to visit the NBC News video interview of Roche’s Karsten Kleine.

Actemra & Rheumatoid Arthritis Drugs

In China, doctors report that they are using anti-inflammation drugs to curb coronavirus effects on critical patients. The drug called Tocilizumab, is sold under the name Actemra and is produced by Roche, a Swiss pharmaceutical giant that also owns Silicon Valley-based Genentech. Chinese doctors are using Tocilizumab to prevent “overreaction of the immune system that has led to organ failure and death in coronavirus patients.”  NBC’s Ms. Emily R. Siegel...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee